Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 versus AMINOSYN II 7 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 versus AMINOSYN II 7 W ELECTROLYTES.
AMINOSYN II 3.5% vs AMINOSYN II 7% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis, providing essential and non-essential nitrogen sources for anabolism in patients unable to tolerate oral or enteral nutrition.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
Intravenous infusion of 250-500 mL/day (8.75-17.5 g amino acids) as a component of parenteral nutrition; rate up to 125 mL/hour; titrate based on metabolic response.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
None Documented
None Documented
Terminal elimination half-life of individual amino acids ranges from 10 to 30 minutes for most, with glutamine and arginine slightly longer (30–45 min). No defined half-life for the mixture; clinically, steady-state achieved in 2–3 hours with continuous infusion.
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
Renal: 95% of infused amino acids are reabsorbed; excess amino acids are deaminated and urea is excreted renally. Fecal/Biliary: negligible (<1%).
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution